Loading patent…
AssigneeOncogen Limited Partnership
InventorsIngegerd Hellstrom, Karl E. Hellstrom, Kim F. Bruce, George J. Schreiber
Estimating the term…
The present invention relates to novel antibodies reactive with human carcinoma cells. More particularly, the antibodies of the invention include: a murine monoclonal antibody, BR96; a human/murine chimeric antibody, ChiBR96; and a F(ab').sub.2 fragment of BR96. These antibodies are reactive with a cell membrane antigen on the surface of human carcinomas. The antibodies display a high degree of selectivity for carcinoma cells and possess the ability to mediate ADCC and CDC activity. In addition, the antibodies of the invention internalize within the carcinoma cells to which they bind. The antibodies also have a unique feature in that they are cytotoxic when used in the unmodified form, at specified concentrations.
Murine monoclonal antibody BR96 produced by the hybridoma HB10036 as deposited with the ATCC.
Hybridoma HB 10036 as deposited with the ATCC.
A recombinant protein which is a murine/human chimeric antibody having (a) a variable region of monoclonal anitbody BR96 produced by hybridoma HB10036 and (b) a constant region of human origin.
An antibody or antigen binding fragment thereof that specifically binds to human carcinoma cells, said anitbody (1) characterized by internalization within the carcinoma cells with which it reacts, mediation of ADCC and CDC activity, and killing of said human carcinoma cells in the absence of host effector cells or complement and (2) having an antigen-binding region of murine monoclonal antibody BR96 produced by hydridoma ATCC No. HB10036 and a constant region of human origin.
Chimeric antibody Chi BR96 produced by the cell line deposited under the accession number HB 10460, said chimeric antibody having an antigen-binding region of murine monoclonal antibody BR96 produced by hybridoma ATCC No. HB10036 and a human IgG.sub.1 constant region.
A cell line deposited under the accession number ATCC HB 10460.
A monoclonal antibody or antigen-binding fragment thereof that specifically binds to human carcinoma cells, wherein said monoclonal antibody and antigen-binding fragment have an antigen-binding region of murine monoclonal antibody BR96 produced by hybridoma ATCC No. 10036.
Dependencies are inferred from the claim text.